Winnipeg Free Press - ONLINE EDITION <\/p>\n
By: Mary Agnes Welch <\/p>\n
Posted: 2:00 AM | Comments: <\/p>\n
CHRIS BOLIN \/ WINNIPEG FREE PRESS Enlarge Image <\/p>\n
Lee Chuckry, who has MS, took part in a stem-cell trial run by Doug Broeska and Regenetek Research. The Airdrie, Alta., man eventually became one of Regenetek's most vocal critics. Photo Store <\/p>\n
Before flying to India for experimental stem-cell therapy, Alberta businessman Lee Chuckry quit taking Tysabri, a drug many multiple-sclerosis patients use to shrink brain lesions and reduce attacks. <\/p>\n
\"It was quite effective for me,\" said Chuckry from his home in Airdrie, Alta. \"I didnt have attacks when I was on it.\" <\/p>\n
Doug Broeska, founder of Winnipeg-based Regenetek Research and the clinical trials principal investigator, told Chuckry that Tysabri would damage the effectiveness of the implanted stem cells. <\/p>\n
Tysabri is one of a long list of medications Broeska advised clinical-trial participants to avoid, all mentioned in a blog posted last fall. <\/p>\n
\"My first attack started just when I was leaving India,\" said Chuckry. \"Id stopped the drug three months before.\" <\/p>\n
<\/p>\n
More here: <\/p>\n
Alberta MS patient says researcher was seen as 'some sort of god'<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Winnipeg Free Press - ONLINE EDITION By: Mary Agnes Welch Posted: 2:00 AM | Comments: CHRIS BOLIN \/ WINNIPEG FREE PRESS Enlarge Image Lee Chuckry, who has MS, took part in a stem-cell trial run by Doug Broeska and Regenetek Research. The Airdrie, Alta., man eventually became one of Regenetek's most vocal critics. Photo Store Before flying to India for experimental stem-cell therapy, Alberta businessman Lee Chuckry quit taking Tysabri, a drug many multiple-sclerosis patients use to shrink brain lesions and reduce attacks. Continue reading